Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

RVX_Anonymous

Jun 01, 2023 04:11PM

Re: Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

jonzobot

Jun 01, 2023 07:24PM

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

in response to

Re: Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

jonzobot

posted on Jun 02, 2023 07:38AM

May not be statistically significant, however, the compassionate use of ZEN 3694 did provide a clinical benefit for both patients. We now have two additional clinical trials that include ZEN 3694 on Zenith's list of great potentials for both the medical profession and Zenith's shareholders. We'll take it as it comes!

"ZEN-3694 is a BET bromodomain inhibitor that directly binds to NUT fusion proteins, disrupts their activity, and inhibits cancer growth."